Apex Biotechnology Corp Total Liabilities
Apex Biotechnology Corp total liabilities. Based on the latest financial reports, Apex Biotechnology Corp (1733) has total liabilities worth NT$494.69 Million TWD (≈ $15.59 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Apex Biotechnology Corp's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Apex Biotechnology Corp (2002–2024)
Total liabilities of Apex Biotechnology Corp from 2002 to 2024. This chart illustrates how Apex Biotechnology Corp's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Apex Biotechnology Corp to see how much of total assets are deployed in long-term investments.
Apex Biotechnology Corp Competitors by Total Liabilities
The table below lists competitors of Apex Biotechnology Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ATW Technology Inc
TWO:8097
|
Taiwan | NT$146.69 Million |
|
Synergy Green Industries Limited
NSE:SGIL
|
India | Rs2.91 Billion |
|
Canadian Net Real Estate Investment Trust
V:NET-UN
|
Canada | CA$180.83 Million |
|
SHIMAO SERV.HLDGS HD-01
F:5GO
|
Germany | €4.98 Billion |
|
q.beyond AG
F:QBY
|
Germany | €37.75 Million |
|
K Laser Technology Inc
TW:2461
|
Taiwan | NT$4.41 Billion |
|
Net Insight AB (publ)
ST:NETI-B
|
Sweden | Skr196.14 Million |
|
Fast Ejendom
CO:FED
|
Denmark | Dkr902.71 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Apex Biotechnology Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 1733 current and non-current assets.
Liquidity & Leverage Metrics
Apex Biotechnology Corp Total Liabilities Ratios Explained
Apex Biotechnology Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apex Biotechnology Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apex Biotechnology Corp (2002–2024)
The table below shows the annual total liabilities of Apex Biotechnology Corp from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$595.70 Million ≈ $18.77 Million |
+19.12% |
| 2023-12-31 | NT$500.07 Million ≈ $15.75 Million |
-28.23% |
| 2022-12-31 | NT$696.81 Million ≈ $21.95 Million |
-24.00% |
| 2021-12-31 | NT$916.91 Million ≈ $28.89 Million |
-8.79% |
| 2020-12-31 | NT$1.01 Billion ≈ $31.67 Million |
-11.61% |
| 2019-12-31 | NT$1.14 Billion ≈ $35.83 Million |
+26.14% |
| 2018-12-31 | NT$901.70 Million ≈ $28.41 Million |
-12.87% |
| 2017-12-31 | NT$1.03 Billion ≈ $32.61 Million |
+34.67% |
| 2016-12-31 | NT$768.49 Million ≈ $24.21 Million |
+0.50% |
| 2015-12-31 | NT$764.69 Million ≈ $24.09 Million |
-1.78% |
| 2014-12-31 | NT$778.52 Million ≈ $24.53 Million |
-3.11% |
| 2013-12-31 | NT$803.47 Million ≈ $25.31 Million |
+9.29% |
| 2012-12-31 | NT$735.18 Million ≈ $23.16 Million |
+89.11% |
| 2011-12-31 | NT$388.76 Million ≈ $12.25 Million |
+21.26% |
| 2010-12-31 | NT$320.60 Million ≈ $10.10 Million |
+5.70% |
| 2009-12-31 | NT$303.31 Million ≈ $9.56 Million |
+37.11% |
| 2008-12-31 | NT$221.21 Million ≈ $6.97 Million |
+8.01% |
| 2007-12-31 | NT$204.80 Million ≈ $6.45 Million |
+4.63% |
| 2006-12-31 | NT$195.73 Million ≈ $6.17 Million |
-12.37% |
| 2005-12-31 | NT$223.36 Million ≈ $7.04 Million |
+73.62% |
| 2004-12-31 | NT$128.64 Million ≈ $4.05 Million |
+5.44% |
| 2003-12-31 | NT$122.00 Million ≈ $3.84 Million |
+36.76% |
| 2002-12-31 | NT$89.21 Million ≈ $2.81 Million |
-- |
About Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more